MMV Dihydroartemisinin- Eurartesim® Treatment of uncomplicated P. falciparum malaria in adults, children and 2015: WHO Cambodia, Thailand 2011: EMA Approved in 19 piperaquine (Sigma-Tau/ infants >5kg. Eurartesim’s long half-life offers excellent protection against prequalification approval countries. More than Pierre Fabre) new infections. This medicine is a treatment of choice in countries four million treatments implementing mass drug administration to accelerate elimination. have been distributed End 2017: since its launch. Expected Registered in 19 submission countries. Eurartesim of has been widely used in dispersible parts of the Asia Pacific paediatric region as a first-line formulation antimalarial and has also to EMA been distributed widely in private sector outlets in the Greater Mekong sub-region. **For these products, FIND has negotiated preferential pricing with diagnostics suppliers for the public sector in low- and middle-income countries (LMICs). Listed countries are eligible for these prices. For more information see: https://www.finddx.org/find-negotiated-product-pricing/ Annex 5: Output - Summary of new/adapted products successfully completing late stage clinical trials with DFAT support (2013-2017) Description of Product/Function Product Name Successfully Trial Stage Completed [What does it treat? PDP Completing Late Trial Locations Intended for use in? Stage Clinical Trial [stage/month/year] What gaps does it fill? (2013-2017) Expected marginal benefit? Partnership Info?] FIND Line Probe Assay Ended Nov 2013 Trial countries: See Annex 4 1st line drugs Germany; Uganda; South Africa; Azerbaijan
MMV Eurartesim® (Sigma-Tau/ Pierre Fabre) Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5kg. Eurartesim’s long half-life offers excellent protection against new infections. This medicine is a treatment of choice in countries implementing mass drug administration to accelerate elimination. 2015: WHO prequalification Cambodia, Thailand 2011: EMA approval End 2017: Expected submission of dispersible paediatric formulation to EMA Approved in 19 countries. More than four million treatments have been distributed since its launch. Registered in 19 countries. Eurartesim has been widely used in parts of the Asia Pacific region as a first-line antimalarial and has also been distributed widely in private sector outlets in the Greater Mekong sub-region. **For these products, FIND has negotiated preferential pricing with diagnostics suppliers for the public sector in low- and middle-income countries (LMICs). Listed countries are eligible for these prices. For more information see: https://www.finddx.org/find-negotiated-product-pricing/ Annex 5: Output - Summary of new/adapted products successfully completing late stage clinical trials with DFAT support (2013-2017) PDP Product Name Successfully Completing Late Stage Clinical Trial (2013-2017) Trial Stage Completed [stage/month/year] Trial Locations Description of Product/Function [What does it treat? Intended for use in? What gaps does it fill? Expected marginal benefit? Partnership Info?] FIND Line Probe Assay 1st line drugs Ended Nov 2013 Trial countries: Germany; Uganda; South Africa; Azerbaijan See Annex 4 Dihydroartemisinin- piperaquine